ALPS Advisors’s Aprea Therapeutics APRE Stock Holding History

ALPS Advisors’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,916	Closed	-$195K	–	903
2021 Q1	$195K	Buy	1,916 +1	+0.1%	+$117	﹤0.01%	854
2020 Q4	$188K	Buy	1,915 +564	+42%	+$268K	﹤0.01%	832
2020 Q3	$650K	Sell	1,351 -85	-6%	-$47.6K	0.01%	397
2020 Q2	$1.11M	Sell	1,436 -472	-25%	-$310K	0.01%	301
2020 Q1	$1.33M	Sell	1,908 -223	-10%	-$164K	0.02%	244
2019 Q4	$1.96M	Buy	+2,131	New	+$1.17M	0.02%	229

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

ALPS Advisors's APRE Position: Q2 2021 in Review

ALPS Advisors sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 1,916 shares — an estimated $195K sold.

ALPS Advisors first reported a position in APRE in Q4 2019 and held it in 6 quarters. The position peaked at $1.96M in Q4 2019. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

ALPS Advisors reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
ALPS Advisors sold 1,916 Aprea Therapeutics shares in Q2 2021, an estimated $195K.
ALPS Advisors first reported a position in Aprea Therapeutics in Q4 2019 and held it in 6 quarters.
ALPS Advisors's Aprea Therapeutics position peaked at $1.96M in Q4 2019.
50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on ALPS Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.